fashion -WSS

fashion

author：knowledge 2025-09-28 21:06:08 - browse：486

The headquarter of Biotechnology company Ionis Pharmaceuticals, consists of glass windows, pale yellow exteriors and plants outside the building — biotech coverage from STAT — courtesy Ionis Pharmaceuticals

Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on Friday that a pair of late-stage trials showed that its experimental therapy for hereditary angioedema benefitted patients — including those taking drugs currently on the market.

In one of the Phase 3 trials, dubbed OASIS, patients with hereditary angioedema, a rare disease characterized by severe bouts of swelling, were given injections of donidalorsen either monthly or every two months. Those in the former group had an 81% lower monthly rate of swelling attacks after 25 weeks than patients given a placebo, while the reduction compared to placebo was 55% for those treated every two months.

The other study, OASISplus, found that donidalorsen’s benefits deepened and converged after up to an additional year of treatment, with swelling attack rates dropping by 92% to 93% regardless of how often patients were dosed. Notably, this study also tracked patients who switched over to donidalorsen from existing therapies meant to prevent swelling attacks, including drugs sold by Takeda and BioCryst Pharmaceuticals. Patients who switched to the Ionis drug saw their swelling attack rates drop by 62% compared to previous treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Lack of health data on LGBTQ+ people has serious consequences

WSS

Use doctors trained outside the U.S. to ease the physician shortage

Immune cells and nerve overgrowth may explain recurring UTI pain

Harvard's David Sinclair gets blowback over aging

First over

State of the Union pitch: Bigger Medicare drug price negotiations

Microsoft's Peter Lee: Generative AI could help doctors be more human

focus

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

What does generative AI mean for health care? We asked experts

Lack of health data on LGBTQ+ people has serious consequences

Activists slam private health insurers over coverage restrictions

Immune cells and nerve overgrowth may explain recurring UTI pain

Peter Hotez and the public health issue of online harassment

Canadians with cystic fibrosis outlive Americans by a decade

Duchenne breakthrough therapy leaves behind pioneering families

Microsoft's Peter Lee: Generative AI could help doctors be more human

Wildfire smoke exposes gaps in outdoor worker protections

Ozempic has benefits for kidney disease as well as diabetes

hotspot

Canadians with cystic fibrosis outlive Americans by a decade

Why Talkspace is targeting Medicare, a tricky market

What affirmative action's end means to a medical student

STAT wants to know your pick for a great summer read or listen

Longer MASH drug regimen improved liver, Akero study finds

For AI in health care standards, federal regulators join with industry group

focus

hotspot

focus

hotspot